Esophageal Cancer Clinical Trials in Beijing, Beijing Municipality
15 recruitingBeijing, Beijing Municipality, China
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled43 locationsNCT06445972
Recruiting
Phase 1Phase 2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled43 locationsNCT06469944
Recruiting
Not Applicable
Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
Esophageal CancerGastric CancerHypoxemia+1 more
Zhejiang University410 enrolled5 locationsNCT07175155
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 1Phase 2
Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer
Esophageal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.105 enrolled30 locationsNCT07367516
Recruiting
Phase 1Phase 2
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Colorectal, CancerEsophageal CancerOvarian Cancer+12 more
Essen Biotech83 enrolled1 locationNCT07410676
Recruiting
Phase 2
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Colorectal, CancerEsophageal CancerGastric Cancer
Sichuan Baili Pharmaceutical Co., Ltd.376 enrolled1 locationNCT06008054
Recruiting
Phase 1
APG-2449 in Patients With Advanced Solid Tumors
Esophageal CancerOvarian CancerNon-small Cell Lung Cancer+2 more
Ascentage Pharma Group Inc.165 enrolled9 locationsNCT03917043
Recruiting
Phase 3
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Esophageal Cancer
Sunshine Lake Pharma Co., Ltd.416 enrolled1 locationNCT04415853
Recruiting
Not Applicable
Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
Esophageal CancerGastric CancerPrecision Screening+2 more
Peking University Cancer Hospital & Institute21,000 enrolled1 locationNCT06306755
Recruiting
Phase 1Phase 2
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
Esophageal CancerStomach CancerStomach Cancer Recurrent+4 more
Essen Biotech75 enrolled1 locationNCT06532799
Recruiting
Phase 2
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences102 enrolled1 locationNCT06498752
Recruiting
Phase 2
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Esophageal Neoplasm MetastaticEsophageal Cancer Stage IVb
Cancer Institute and Hospital, Chinese Academy of Medical Sciences120 enrolled1 locationNCT06084897
Recruiting
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Breast CancerLiver CancerColorectal, Cancer+10 more
Beijing Friendship Hospital2,700 enrolled4 locationsNCT06363123
Recruiting
Phase 3
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Esophageal Cancer
Chinese Academy of Medical Sciences300 enrolled1 locationNCT03731442